Last updated: November 11th, 2025
The European Joint Clinical Assessment (JCA) is changing how pharma and biotech companies plan for market access. A well-prepared JCA dossier does more than accelerate review, as it positions therapies competitively across diverse healthcare systems. Drawing on practical experience and industry insights, we highlight seven lessons that can help companies build a comprehensive, well-aligned dossier.
1. Anticipate Local Clinical “Deltas” Beyond the JCA Package
Myth: No additional clinical evidence is needed beyond JCA.
Many teams assume that once the JCA submission is complete, the clinical evidence requirements are fully met. In practice, national HTA agencies may request extra analyses, local data, or added validation of results after the joint assessment ends. These “local delta dossiers” can delay reimbursement if not anticipated early.
What to do:
Map potential country-specific evidence needs during early planning.
Identify where additional subgroup analyses, registry data, or RWE may be required.
Create modular evidence packages that can be efficiently tailored for each HTA.
Tip: Establish a tracking system that links JCA evidence modules to each country’s submission requirements, ensuring agility when adjustments are needed.
2. Prepare for Multiple PICO Scenarios
Myth: You only need one PICO.
A single PICO framework rarely captures all potential assessment pathways. Depending on the therapeutic area, the JCA may define several Potential Indication–Comparator–Outcome (PICO) combinations, each requiring distinct evidence considerations.
What we do:
- Run early PICO predictions, using PICO Predict, an expert-led, AI-enabled approach.
Validate PICO assumptions with affiliates and clinical experts.
Build flexible evidence packages (ITCs, NMAs) that cover multiple possible scenarios and defend those that cannot be addressed.
Tip: Maintain adaptable datasets and modular analyses that can support multiple PICOs, while not compromising methodological integrity.
3. Align Regulatory and JCA Evidence Early
Myth: European Medicines Agency (EMA) dossier evidence is sufficient.
While regulatory dossiers are designed to meet EMA standards, JCA expectations often differ. Consequently, many EMA submissions lack key comparators, outcomes, or patient-reported measures prioritized by HTA reviewers, resulting in additional data requests and delayed timelines.
What we do:
Audit EMA data against likely JCA scopes to identify missing comparators or outcomes.
Leverage real-world evidence and registry data to address identified evidence gaps.
Incorporate surrogate or interim outcomes strategically when long-term data are still maturing.
Tip: Create a unified evidence repository that captures both regulatory and access-oriented data for consistent, quick access during submission development.
4: Demonstrate Meaningful Outcomes
Myth: Outcomes are interchangeable, pick the easiest.
HTA reviewers evaluate value through outcomes that reflect real-world benefit, not just clinical efficacy. Therefore, including measurements like survival, quality-of-life, tolerability, and patient-reported outcomes increases the dossier’s relevance and credibility.
What we do:
Integrate PROs, QoL, and other patient-centered outcomes early.
Justify surrogate endpoints transparently.
Ensure measurement consistency and external validity across studies.
Tip: Ensure endpoint definitions are consistent across studies and supported by credible measurement methods.
5: Begin Evidence Planning Before Scoping Starts
Myth: The scoping process will capture everything.
The JCA scoping process sets the plan but doesn’t capture all future evidence needs. Relying solely on it can leave emerging comparators or outcomes unaddressed, requiring reactive fixes later.
What we do:
Start internal pre-scoping preparation early.
Maintain a living evidence landscape that tracks data readiness.
Engage in Joint Scientific Consultations or structured advice to confirm key evidence assumptions.
Tip: Pair internal planning with external scientific advice or early dialogue to validate assumptions and strengthen submission confidence.
6: Treat Indirect Evidence as Core, Not Contingent
Myth: Indirect evidence will be a last resort.
When direct comparisons are limited, indirect comparisons and network meta-analyses (NMAs) become essential tools for demonstrating relative value. However, treating them as backup analyses can weaken the dossier and delay responses to reviewers.
What we do:
Build ITC/NMA capability early within the evidence strategy.
Identify and integrate real-world evidence to strengthen comparative analyses.
Quantify uncertainty transparently through planned sensitivity analyses.
Tip: Develop adaptable analytical models early to efficiently support multiple comparator scenarios.
7: Integrate JCA Insights into a Broader Market Access Strategy
Myth: One EU clinical story will be enough.
While the JCA aligns elements of clinical assessment, it does not replace country-level evaluation. Insights from JCA should inform broader market access strategies, guiding launch sequencing, evidence generation, and affiliate coordination.
What we do:
Maintain a core clinical “spine” for JCA.
Layer national modules for key markets (e.g., DE, FR, IT, ES, PL, etc.).
Secure early affiliate input to ensure alignment with local HTA norms.
Tip: Build a feedback loop between European and country access teams to refine approaches and strengthen alignment.
Our Expertise in Navigating the JCA Landscape
As the Joint Clinical Assessment changes how evidence supports access decisions, companies need more than process readiness. They need partners who understand how regulatory, clinical, and market access goals connect.
With this in mind, our team brings hands-on experience guiding companies through every stage of JCA preparation. We also help align global and local evidence needs, identify data gaps, and create submissions that meet reviewer expectations, turning JCA challenges into opportunities for faster, more coordinated access across Europe.
Ready to see how PICO Predict strengthens your JCA dossier?
Meet The Author
Mohammed Madkour
Manager, HEOR and Access
Mohammed has over six years of experience in the pharmaceutical industry, focusing on reimbursement, evidence generation, and dossier development across the UK, Europe, and MENA. He specializes in HTA submissions, economic evaluations, and pricing strategy, and is deepening his expertise in HEOR statistical methods to strengthen evidence-based decision-making.
FAQs on VPAG and Medicines Access
What is a JCA dossier?
A comprehensive evidence package used by European HTA bodies to evaluate a medicine’s clinical and economic value.Why isn’t EMA evidence always enough?
Regulatory data may not cover all comparators, outcomes, or population analyses required by JCA scopes.How many PICO scenarios should companies prepare for?
Multiple, based on early scoping; planning for flexibility is critical.What are common evidence gaps in JCA submissions?
Missing local data, real-world evidence, or patient-reported outcomes.How can pharma improve chances of successful market access?
By aligning evidence with JCA expectations, preparing for follow-up queries, and integrating insights into national submissions.